Objective To compare the efficacy and safety of sodium zirconium cyclosilicate and calcium polystyrene sulphonate in the treatment of hyperkalemia in chronic kidney disease(CKD).Methods Hospitalized patients with CKD hyperkalemia admitted to Qingyuan People's Hospital from January 2022 to November 2023 were retrospectively selected as study objects,and were divided into sodium zirconium cyclosilicate group and calcium polystyrene sulphonate group according to different drug use.The two groups of patients were matched with 1:1 propensity score,and finally 43 pairs of data were successfully matched.The efficacy and incidence of adverse reactions were compared between two groups of patients after matching.Results After treatment,the serum potassium level in both groups was significantly lower than that before treatment(P<0.05),but there was no significant difference in serum potassium level between two groups(P>0.05).There was no significant difference in the total effective rate between two groups(χ2=1.242,P=0.537).After treatment,the blood sodium level in sodium zirconium cyclosilicate group was significantly higher than that before treatment(P<0.05),there was no significant difference in blood calcium level before and after treatment(P>0.05).There was no significant difference in serum sodium and serum calcium before and after treatment in calcium polystyrene sulphonate group(P>0.05).There was one patient with hypokalemia in each group,and no treatment related adverse reactions such as nausea,edema,constipation,abdominal bloating and diarrhea were observed,and no abnormal laboratory test results were found.Conclusion The clinical efficacy of sodium zirconium cyclosilicate and calcium polystyrene sulphonate in treatment of hyperkalemia in CKD patients is comparable,and the safety is good.

Objective To explore the feasibility and safety of transumbilical laparoendoscopic single-site surgery(TU-LESS)in the treatment of gynecologic malignant neoplasms.Methods The data of 363 patients with gynecologic malignant neoplas from November 2017 to October 2021 were collected for retrospective study.There were 123 cases of endometrial cancer[4 cases of robotic TU-LESS(R-TU-LESS)],211 cases of cervical cancer(16 cases of R-TU-LESS),and 29 cases of ovarian cancer(1 case of R-TU-LESS).Data collection included operation-related characteristics,postoperative rehabilitation indicators and oncological outcomes.Results ①Feasibility:the surgical conversion rate of the three groups was 3.3%(4/123),4.3%(9/211),and 6.9%(2/29),and the average operation duration was(213.8±64.3)min,(288.8±85.6)min,and(307.0±73.6)min,respectively.②Safety:the median value of blood loss during surgery of the three groups was 50(50,100)ml,100(50,200)ml,and 100(65,325)ml,the intraoperative complications rate was 3.3%(4/123),4.7%(10/211),and 17.2%(5/29),the postoperative complications rate was 7.3%(9/123),11.4%(24/211),and 17.2%(5/29),the median follow up time was 42.1(23.3,69.6)months,41.5(23.3,70.6)months,and 39.9(23.1,65.5)months,the five-year disease-free survival(DFS)was 92.3%,93.3%,and 84.4%,and the five-year overall survival(OS)was 96.8%,94.5%,and 88.5%,respectively.Conclusion TU-LESS is a safe and feasible approach for the treatment of gynecologic malignant neoplasms.

Objective To compare the efficacy and safety of sodium zirconium cyclosilicate and calcium polystyrene sulphonate in the treatment of hyperkalemia in chronic kidney disease(CKD).Methods Hospitalized patients with CKD hyperkalemia admitted to Qingyuan People's Hospital from January 2022 to November 2023 were retrospectively selected as study objects,and were divided into sodium zirconium cyclosilicate group and calcium polystyrene sulphonate group according to different drug use.The two groups of patients were matched with 1:1 propensity score,and finally 43 pairs of data were successfully matched.The efficacy and incidence of adverse reactions were compared between two groups of patients after matching.Results After treatment,the serum potassium level in both groups was significantly lower than that before treatment(P<0.05),but there was no significant difference in serum potassium level between two groups(P>0.05).There was no significant difference in the total effective rate between two groups(χ2=1.242,P=0.537).After treatment,the blood sodium level in sodium zirconium cyclosilicate group was significantly higher than that before treatment(P<0.05),there was no significant difference in blood calcium level before and after treatment(P>0.05).There was no significant difference in serum sodium and serum calcium before and after treatment in calcium polystyrene sulphonate group(P>0.05).There was one patient with hypokalemia in each group,and no treatment related adverse reactions such as nausea,edema,constipation,abdominal bloating and diarrhea were observed,and no abnormal laboratory test results were found.Conclusion The clinical efficacy of sodium zirconium cyclosilicate and calcium polystyrene sulphonate in treatment of hyperkalemia in CKD patients is comparable,and the safety is good.

Objective To explore the feasibility and safety of transumbilical laparoendoscopic single-site surgery(TU-LESS)in the treatment of gynecologic malignant neoplasms.Methods The data of 363 patients with gynecologic malignant neoplas from November 2017 to October 2021 were collected for retrospective study.There were 123 cases of endometrial cancer[4 cases of robotic TU-LESS(R-TU-LESS)],211 cases of cervical cancer(16 cases of R-TU-LESS),and 29 cases of ovarian cancer(1 case of R-TU-LESS).Data collection included operation-related characteristics,postoperative rehabilitation indicators and oncological outcomes.Results ①Feasibility:the surgical conversion rate of the three groups was 3.3%(4/123),4.3%(9/211),and 6.9%(2/29),and the average operation duration was(213.8±64.3)min,(288.8±85.6)min,and(307.0±73.6)min,respectively.②Safety:the median value of blood loss during surgery of the three groups was 50(50,100)ml,100(50,200)ml,and 100(65,325)ml,the intraoperative complications rate was 3.3%(4/123),4.7%(10/211),and 17.2%(5/29),the postoperative complications rate was 7.3%(9/123),11.4%(24/211),and 17.2%(5/29),the median follow up time was 42.1(23.3,69.6)months,41.5(23.3,70.6)months,and 39.9(23.1,65.5)months,the five-year disease-free survival(DFS)was 92.3%,93.3%,and 84.4%,and the five-year overall survival(OS)was 96.8%,94.5%,and 88.5%,respectively.Conclusion TU-LESS is a safe and feasible approach for the treatment of gynecologic malignant neoplasms.

Objective:To construct NMB0315 eukaryotic expression recombinant vector ,detect specific humoral and cellular immune response induced by the recombint DNA vaccine intramuscularly in female BALB /c mice,evaluate the immunocompetence and immunoprotection of the vaccine , so as to provide experimental basis for the development of a novel nucleic acid vaccine against N.meningitidis serogroup B .Methods: The whole NMB0315 gene was amplified by PCR from the standard strains MC 58 genomic DNA,cloned into a plasmid pcDNA3.1(+),identified by double digestion of the recombinant plasmid with restriction enzymes and se -quencing.The recombinant vector pcDNA 3.1 (+)/NMB0315 was transfected into eukaryotic COS-7 cells and RAW264.7 cells, the NMB0315 protein was detected by immunocytochemical method and Western blot respectively .The levels of specific humoral and cellular immune response were detected after inoculating in female BALB /c mice intramuscularly with the recombinant plasmid .The immune protective effect was investigated with the DNA vaccine and the bactericidal titer of the immune serum was deter mined by serum bactericidal assay ( SBA ) in vitro.Results: The recombinant pcDNA3.1 (+)/NMB0315 was effectively transcripted and expressed in eukaryotic cells and the specific humoral and cellular immune responses were induced in the inoculated mice .In the re-combinant pcDNA3.1(+)/NMB0315 group ,the levels of serum IgG,IgG1,IgG2a,IgG2b and IgG3 and genital tract sIgA were significantly higher than in controls ( P<0.001 ) .The stimulation index in the culture supernatant of the spleen lymphocytes of the vaccine group was higher than that of the control group (P<0.05).The ratios of serum IgG2a/IgG1 in the DNA vaccine group were less than 1.The bactericidal titer of the NMB 0315+CpG group reached 1:128 following three immunizations , the protection rate of the vaccine group was 70%against the N.meningitidis strain MC58.Conclusion:The NMB0315 nucleic acid vaccine could induce higher levels of humoral immunity and cellular immunity and showed effective protection against N .meningitidis serogroup B , the immune serum had strong bactericidal activity in vitro .